Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas

Huang,Yinxing; Ding,Chenyu; Zhang,Fangfang; Xiao,Deyong; Zhao,Lin; Wang,Shousen

doi:10.3892/ol.2017.7462

Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas

Authors:
- Yinxing Huang
- Chenyu Ding
- Fangfang Zhang
- Deyong Xiao
- Lin Zhao
- Shousen Wang
View Affiliations

Affiliations: Department of Neurosurgery, Fuzhou General Hospital, Fujian Medical University, Fuzhou, Fujian 35002, P.R. China, Department of Neurosurgery, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China, Department of Endocrinology, First Hospital of Fuzhou Affiliated to Fujian Medical University, Fuzhou, Fujian 350009, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China
Published online on: November 21, 2017 https://doi.org/10.3892/ol.2017.7462
Pages: 2010-2016

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the function of the prolactin/adenoma maximum diameter (PRL/MD) and the prolactin/adenoma volume (PRL/V) in the differential diagnosis of prolactinomas and other types of pituitary adenomas. A total of 118 patients with pituitary adenoma, hyperprolactinemia and a plasma PRL <250 µg/l were enrolled. Clinical data from these patients were retrospectively analyzed. A receiver operating characteristic curve was plotted. The function of PRL, PRL/MD and PRL/V in the differential diagnosis of prolactinomas and other types of pituitary adenomas was compared. The results revealed that a PRL of 55.65 µg/l was the most accurate [sensitivity (SE), 0.800; specificity (SP), 0.716; positive predictive value (PPV), 0.857; negative predictive value (NPV), 0.933; and Youden index (YI), 0.516]. The PRL/MD with the highest diagnostic value was 4.03 µg/(l x mm) (SE, 0.800; SP, 0.898; PPV, 0.727; NVP, 0.929; and YI, 0.698). The PRL/V with the highest diagnostic value was 54.00 µg/(l x cm3) (SE, 0.900; SP, 0.966; PPV, 0.900; NVP, 0.966; and YI, 0.866). The PRL/MD tended to be of higher diagnostic accuracy than PRL, but this difference was not statistically significant (P=0.097). The differentiation ability of PRL/V was significantly stronger than that of PRL (P=0.028). Thus, serum PRL, PRL/MD and PRL/V levels may be able to differentiate prolactinomas from other types of hyperprolactinemia‑causing pituitary adenomas prior to treatment. PRL/V may be better than the PRL level in achieving a differential diagnosis, and the optimal PRL/V ratio for differentiating prolactinomas from other types of hyperprolactinemia‑causing pituitary adenomas was 54.00 µg/(l x cm3).

View Figures

View References

1	Wass JA and Karavitaki N: Nonfunctioning pituitary adenomas: The oxford experience. Nat Rev Endocrinol. 5:519–522. 2009. View Article : Google Scholar : PubMed/NCBI
2	Capozzi A, Scambia G, Pontecorvi A and Lello S: Hyperprolactinemia: Pathophysiology and therapeutic approach. Gynecol Endocrinol. 31:506–510. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sakurai T, Seo H, Yamamoto N, Nagaya T, Nakane T, Kuwayama A, Kageyama N and Matsui N: Detection of mRNA of prolactin and ACTH in clinically nonfunctioning pituitary adenomas. J Neurosurg. 69:653–659. 1988. View Article : Google Scholar : PubMed/NCBI
4	Beentjes JA, Tjeerdsma G, Sluiter WJ and Dullaart RP: Divergence between growth hormone responses to insulin-induced hypoglycaemia and growth hormone-releasing hormone in patients with non-functioning pituitary macroadenomas and hyperprolactinaemia. Clin Endocrinol (Oxf). 45:391–398. 1996. View Article : Google Scholar : PubMed/NCBI
5	Fonseca AL, Chimelli L, Santos MJ, Santos AA and Violante AH: Influence of hyperprolactinemia and tumoral size in the postoperative pituitary function in clinically nonfunctioning pituitary macroadenomas. Arq Neuropsiquiatr. 60:590–602. 2002.(In Portuguese). View Article : Google Scholar : PubMed/NCBI
6	Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE and Wass JA: Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf). 65:524–529. 2006. View Article : Google Scholar : PubMed/NCBI
7	Cury ML, Fernandes JC, Machado HR, Elias LL, Moreira AC and Castro Md: Non-functioning pituitary adenomas: Clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq Bras Endocrinol Metabol. 53:31–39. 2009. View Article : Google Scholar : PubMed/NCBI
8	Berkmann S, Fandino J, Muller B, Remonda L and Landolt H: Intraoperative MRI and endocrinological outcome of transsphenoidal surgery for non-functioning pituitary adenoma. Acta Neurochir (Wien). 154:639–647. 2012. View Article : Google Scholar : PubMed/NCBI
9	Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G and Savastano S: Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 15:905–915. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zhao W, Ye H, Li Y, Zhou L, Lu B, Zhang S, Wen J, Li S, Yang Y and Hu R: Thyrotropin-secreting pituitary adenomas: Diagnosis and management of patients from one Chinese center. Wien Klin Wochenschr. 124:678–684. 2012. View Article : Google Scholar : PubMed/NCBI
11	Behan LA, O'sullivan EP, Glynn N, Woods C, Crowley RK, Tun TK, Smith D, Thompson CJ and Agha A: Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas. J Endocrinol Invest. 36:508–514. 2013.PubMed/NCBI
12	Shimon I, Jallad RS, Fleseriu M, Yedinak CG, Greenman Y and Bronstein MD: Giant GH-secreting pituitary adenomas: Management of rare and aggressive pituitary tumors. Eur J Endocrinol. 172:707–713. 2015. View Article : Google Scholar : PubMed/NCBI
13	Ferrante E, Ferraroni M, Castrignanò T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, et al: Non-functioning pituitary adenoma database: A useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol. 155:823–829. 2006. View Article : Google Scholar : PubMed/NCBI
14	Hong JW, Lee MK, Kim SH and Lee EJ: Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma. Endocrine. 37:140–147. 2010. View Article : Google Scholar : PubMed/NCBI
15	Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA and Wass JA; Endocrine Society, : Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 96:273–288. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zhu M, Zhang Y and Peng H: Comparative Analysis and Clinical Application of Serum PRL and MRI Scan on Pituitary Prolactinoma. J Radioimmunol. 2013.
17	Smith MV and Laws ER Jr: Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: Lack of correlation with serum prolactin levels. Neurosurgery. 34:834–839. 1994. View Article : Google Scholar : PubMed/NCBI
18	Delellis RA: Pathology and genetics of tumours of endocrine organs. IARC Press; 2004
19	Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, et al: A new prognostic clinicopathological classification of pituitary adenomas: A multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
20	Jan M, Dufour H, Brue T and Jaquet P: Prolactinoma surgery. Ann Endocrinol (Paris). 68:118–119. 2007. View Article : Google Scholar : PubMed/NCBI
21	Gruppetta M and Vassallo J: Epidemiology and radiological geometric assessment of pituitary macroadenomas: Population-based study. Clin Endocrinol (Oxf). 85:223–231. 2016. View Article : Google Scholar : PubMed/NCBI
22	Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S and Teramoto A: Pathology of the human pituitary adenomas. Histochem Cell Biol. 130:495–507. 2008. View Article : Google Scholar : PubMed/NCBI
23	Barkan AL and Chandler WF: Giant pituitary prolactinoma with falsely low serum prolactin: The pitfall of the ‘high-dose hook effect’: Case report. Neurosurgery. 42:913–916. 1998. View Article : Google Scholar : PubMed/NCBI
24	Petakov MS, Damjanović SS, Nikolić-Durović MM, Dragojlović ZL, Obradović S, Gligorović MS, Simić MZ and Popović VP: Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest. 21:184–188. 1998. View Article : Google Scholar : PubMed/NCBI
25	Romijn JA: Hyperprolactinemia and prolactinoma. Handb Clin Neurol. 124:185–195. 2014. View Article : Google Scholar : PubMed/NCBI
26	Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R Jr, Barros AI, Faria M, Nascimento GC, Lima JG, et al: Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 31:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
27	Paepegaey AC, Veron L, Wimmer MC and Christin-Maitre S: Misleading diagnosis of hyperprolactinemia in women. Gynecol Obstet Fertil. 44:181–186. 2016.(In French). View Article : Google Scholar : PubMed/NCBI
28	Kawaguchi T, Ogawa Y and Tominaga T: Diagnostic pitfalls of hyperprolactinemia: The importance of sequential pituitary imaging. BMC Res Notes. 7:5552014. View Article : Google Scholar : PubMed/NCBI
29	Ross RJ, Grossman A, Bouloux P, Rees LH, Doniach I and Besser GM: The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with pituitary macroadenomas. Clin Endocrinol (Oxf). 23:227–235. 1985. View Article : Google Scholar : PubMed/NCBI
30	Arafah BM, Nekl KE, Gold RS and Selman WR: Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab. 80:3507–3512. 1995. View Article : Google Scholar : PubMed/NCBI
31	Pala NA, Laway BA, Misgar RA and Dar RA: Metabolic abnormalities in patients with prolactinoma: Response to treatment with cabergoline. Diabetol Metab Syndr. 7:992015. View Article : Google Scholar : PubMed/NCBI
32	Wong A, Eloy JA, Couldwell WT and Liu JK: Update on prolactinomas. Part. 2:Treatment and management strategies. J Clin Neurosci 22: 1568–1574. 2015.
33	Menucci M, Quinones-Hinojosa A, Burger P and Salvatori R: Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary. 14:68–74. 2011. View Article : Google Scholar : PubMed/NCBI